In 2023 the firm abandoned development of lotiglipron after trial participants showed elevated liver enzymes, and the same year discontinued a twice-daily danuglipron dosing regime after almost three quarters of treated patients experienced nausea, while almost a half developed vomiting and a quarter diarrhoea
What the Phase 3 doses tell us The Phase 3 maintenance doses of 4mg, 9mg, and 12mg represent a refinement of the Phase 2 protocol
Hopkins ND, Cuthbertson DJ, Kemp GJ, Pugh C, Green DJ, Cable NT, et al
Yunfeng Liu, [email protected] These authors have contributed equally to this work and share first authorship These authors have contributed equally to this work This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology ORCID: Yi Zhang, orcid.org/0000-0003-0305-3127 Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers